Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by Xijing Hospital
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01652560
First received: July 21, 2012
Last updated: July 25, 2012
Last verified: July 2012

July 21, 2012
July 25, 2012
June 2012
June 2014   (final data collection date for primary outcome measure)
Objective Response Rate [ Time Frame: From enrollment to disease progression ] [ Designated as safety issue: No ]
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Same as current
Complete list of historical versions of study NCT01652560 on ClinicalTrials.gov Archive Site
overall response [ Time Frame: From enrollment to disease progression ] [ Designated as safety issue: No ]
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Same as current
Not Provided
Not Provided
 
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Breast cancer patients of vascular endocrine surgery department in Xijing Hospital

  • Breast Cancer
  • Bevacizumab
  • Neoadjuvant Chemotherapy
  • Molecular Targeted Therapy
Drug: bevacizumab
The patients will be treated with Avastin combined neoadjuvant chemotherapy
Other Name: Avastin
bevacizumab combined neoadjuvant chemotherapy
Intervention: Drug: bevacizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
September 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HER2-negative breast cancer patients
  • Without surgery
  • Plans to neoadjuvant chemotherapy

Exclusion Criteria:

  • HER2-positive breast cancer patients
  • Post-operative patients
Both
18 Years to 75 Years
No
Contact: Nanlin Li, Phd +86-186-2963-7041 nanlin-74@163.com
Contact: Hongyu Xiao, Master +86-186-2963-7040 louch2008@116.com
China
 
NCT01652560
QTDS-01
No
LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Roche Pharma AG
Not Provided
Xijing Hospital
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP